Related Experiment Video
Updated: May 16, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Telaprevir for chronic hepatitis C virus infection
Arun B Jesudian1, Ira M Jacobson
1Division of Gastroenterology and Hepatology, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, USA. arun.jesudian@gmail.com
Telaprevir, a direct-acting antiviral, significantly boosts sustained virologic response rates in hepatitis C virus (HCV) genotype 1 patients. Common side effects include anemia, rash, and anorectal discomfort.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis C virus (HCV) infection is a major global health concern.
- Direct-acting antivirals represent a significant advancement in HCV treatment.
- Telaprevir targets the HCV NS3/4A serine protease, crucial for viral replication.
Purpose of the Study:
- To evaluate the efficacy of telaprevir-containing regimens for HCV genotype 1.
- To compare treatment outcomes with standard pegylated interferon and ribavirin therapy.
Main Methods:
- Analysis of Phase 2b and 3 clinical trial data.
- Inclusion of both treatment-naïve and treatment-experienced patient populations.
- Assessment of sustained virologic response rates.
Main Results:
- Telaprevir-containing regimens demonstrated a marked increase in sustained virologic response rates.
- Efficacy was observed in both treatment-naïve and treatment-experienced patients with HCV genotype 1.
- Common adverse events included anemia, eczematous rash, and anorectal discomfort.
Conclusions:
- Telaprevir offers a more effective treatment option for HCV genotype 1 compared to standard therapy.
- Understanding and managing side effects like anemia and rash is crucial for patient management.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Retroviruses
Inhibitors of Viral Protein Synthesis
Subviral Agents